an updated analysis of echelon-1: 1l brentuximab vedotin chemotherapy in stage iii/iv classical hl
Published 2 years ago • 538 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
4:52
phase iii echelon-1 study: updated results of brentuximab vedotin chemotherapy for untreated chl
-
1:41
echelon-1 aya subgroup results: brentuximab vedotin plus avd vs. abvd
-
1:02
seven-year os analysis from echelon-1: brentuximab vedotin avd versus abvd in hodgkin lymphoma
-
3:09
real-world efficacy of brentuximab vedotin as consolidation therapy in patients with hl
-
2:28
recent updates from echelon-1 and implications for the treatment of hl
-
5:06
5-year follow-up of echelon-1: brentuximab plus avd versus abvd in hodgkin lymphoma
-
32:56
echo analyzer monthly maintenance
-
![analyzing hundreds of markers in a single tumor section [webinar]](https://i.ytimg.com/vi/RAb-SJdrnos/mqdefault.jpg)
33:57
analyzing hundreds of markers in a single tumor section [webinar]
-
1:59:16
thieme webcheminars #1: click and bioorthogonal chemistry
-
5:36
updates from the echelon-1 study
-
4:27
an analysis of older patients treated with brentuximab vedotin in the echelon-1 trial
-
1:11
brentuximab vedotin: current status and future considerations for this agent in hl treatment
-
2:47
hodgkin lymphoma updates in the uk: echelon-1
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
3:23
brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical hodgkin lymphoma
-
2:00
a 10-year pfs simulation model based on the echelon-1 trial in hodgkin lymphoma
-
1:32
updated echelon-1 findings demonstrate potential toxicities of brentuximab vedotin combo in chl
-
9:41
echelon-1 study of brentuximab vedotin as frontline therapy for hodgkin's lymphoma
-
2:41
echelon-1 trial updates: overall survival data
-
3:21
brentuximab vedotin nivolumab in lymphoma
-
1:55
updated 3-year findings of echelon-1 trial presented for classical hodgkin lymphoma
-
3:09
echelon-1 trial data from ash 2017: controversies and clinical translation